Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 18, 2012
CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential
Safiehkhatoon Moshkani, Igor I Kuzin, Funmilola Adewale, et al.
Pharmacology Research & Perspectives
|
September 5, 2024
Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant
Timothy Waterhouse, Kyle Baron, Westley Eure, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 21, 2008
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells
Faith M Young, Andrew Campbell, Kris Lambert Emo, et al.
Frontiers in Neurology
|
April 6, 2026
Hidden diagnoses among patients with double seronegative myasthenia gravis
Vukan Ivanovic, Stojan Peric, Caitlin Briggs, et al.
Blood Advances
|
December 11, 2019
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Yi-Bin Chen, Nirav N Shah, Anne S Renteria, et al.
Stem Cells (Dayton, Ohio)
|
May 14, 2013
Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons
Maria Sundberg, Helle Bogetofte, Tristan Lawson, et al.
Journal of Cancer
|
October 6, 2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
Ryan J Sullivan, Katy K Tsai, Anna C Pavlick, et al.
Nature Medicine
|
June 6, 2024
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Yi-Bin Chen, Mohamad Mohty, Robert Zeiser, et al.
Bone Marrow Transplantation
|
June 10, 2021
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
Yngvar Fløisand, Mark A Schroeder, Patrice Chevallier, et al.
International Journal of Hematology
|
March 12, 2025
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study
Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 18, 2012
CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential
Safiehkhatoon Moshkani, Igor I Kuzin, Funmilola Adewale, et al.
Pharmacology Research & Perspectives
|
September 5, 2024
Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant
Timothy Waterhouse, Kyle Baron, Westley Eure, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 21, 2008
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells
Faith M Young, Andrew Campbell, Kris Lambert Emo, et al.
Frontiers in Neurology
|
April 6, 2026
Hidden diagnoses among patients with double seronegative myasthenia gravis
Vukan Ivanovic, Stojan Peric, Caitlin Briggs, et al.
Blood Advances
|
December 11, 2019
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Yi-Bin Chen, Nirav N Shah, Anne S Renteria, et al.
Stem Cells (Dayton, Ohio)
|
May 14, 2013
Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons
Maria Sundberg, Helle Bogetofte, Tristan Lawson, et al.
Journal of Cancer
|
October 6, 2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
Ryan J Sullivan, Katy K Tsai, Anna C Pavlick, et al.
Nature Medicine
|
June 6, 2024
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Yi-Bin Chen, Mohamad Mohty, Robert Zeiser, et al.
Bone Marrow Transplantation
|
June 10, 2021
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
Yngvar Fløisand, Mark A Schroeder, Patrice Chevallier, et al.
International Journal of Hematology
|
March 12, 2025
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study
Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, et al.
Page
of 2